Drug Profile
Research programme: anticancer therapies - Verseon
Latest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Verseon
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 01 Jan 2016 Preclinical trials in Solid tumours in USA (unspecified route) (Verseon pipeline, January 2016)